This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): LNK 754
Description: LNK-754 is a farnesyl-transferase inhibitor. It is proposed to treat proteinopathies by interfering with farnesylation of proteins in the autophagy pathway, increasing clearance of abnormal proteins. Doses are lower than those needed impact the farnesylation of Ras in treating cancers, which is hoped to lessen side effects.
Deal Structure: The compound was licensed from an undisclosed pharmaceutical company, which had unsuccessfully tested the drug in clinical trials for a different illness.
Link and AstraZeneca
In July 2012, AstraZeneca acquired multiple small molecule assets from Link in clinical and preclinical stage that target the enzyme farnesyltransferase and modulate autophagy. Under the terms of the agreement, AstraZeneca will make specified upfront and milestone payments and will assume all of the programmes research and development activities. The financial terms of the deal have not been disclosed.
Partners: Link Medicine Corporation
Additional information available to subscribers only: